A phase II feasibility study of carboplatin and nab‐paclitaxel for advanced non‐small cell lung cancer patients with interstitial lung disease (YLOG0114)

A phase II feasibility study of carboplatin and nab‐paclitaxel for advanced non‐small cell lung cancer patients with interstitial lung disease (YLOG0114)

Abstract Background A standard treatment regimen for advanced non‐small cell lung cancer (NSCLC) patients with interstitial lung disease (ILD) has not been established since most clinical trials exclude such patients because of the high risk of acute exacerbation of ILD. This study aimed to prospect...

Full description

Bibliographic Details
Main Authors: Hiroyuki Sakashita, Ken Uchibori, Yasuto Jin, Toshiharu Tsutsui, Takayuki Honda, Rie Sakakibara, Takahiro Mitsumura, Yoshihisa Nukui, Tsuyoshi Shirai, Masahiro Masuo, Kozo Suhara, Haruhiko Furusawa, Takaaki Yamashita, Takehiko Ohba, Kazuhito Saito, Jun Takagiwa, Yoshihiro Miyashita, Naohiko Inase, Yasunari Miyazaki
Format: Article
Language:English
Published: Wiley 2022-05-01
Series:Thoracic Cancer
Subjects:
carboplatin
interstitial lung disease
nab‐paclitaxel
non‐small‐cell lung cancer
Online Access:https://doi.org/10.1111/1759-7714.14376

Internet

https://doi.org/10.1111/1759-7714.14376

Similar Items